FindTrial
Sign In

Mebendazole as Adjuvant Treatment for Colon Cancer

Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03925662
Enrollment
40
Registered
2019-04-24
Start date
2019-04-01
Completion date
2028-12-31
Last updated
2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

mebendazole treating colon cancer

Detailed description

mebendazole as adjuvant treatment for colon cancer

Interventions

DRUGFolfox with avastin

Folfox with avastin only

DRUGMebendazole

Folfox with avastin with mebendazole

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Colorectal cancer stage 4.

Exclusion criteria

* Agranulocytosis * Pregnancy * Allergy to mebendazole.

Design outcomes

Primary

MeasureTime frameDescription
number of patients with tumour response6 monthsnumber of patients with response

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026